University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to
University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to address software fusion requirements as a complement to conventional hardware-based techniques. The hospital has been working with PET/CT imaging since October 2001. The collaboration is the first step toward establishing R&D partnerships among leading European institutions, CTI, and its subsidiaries, including Mirada Solutions and PETNET Pharmaceuticals. Mirada joined CTI Aug. 18, when CTI purchased all of Mirada's capital stock.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.